[
  {
    "ts": null,
    "headline": "FDA Flags Alarming Contamination At Novo Nordisk Indiana Plant, Including Cat Hair, Bacteria, And Foreign Particles",
    "summary": "The U.S. Food and Drug Administration (FDA) has identified repeated quality control failures, including foreign particle contamination, inadequate investigations, and insufficient corrective actions at the Novo Nordisk A/S (NYSE:NVO) operated facility in Bloomington, Indiana. In 2024, Novo Nordisk acquired three fill-finish sites from Novo Holdings A/S for $11 billion. The acquisition was part of a larger deal where Novo Holdings acquired Catalent, Inc. (NYSE:CTLT). The three sites, located in A",
    "url": "https://finnhub.io/api/news?id=9d25aa61667a4b9a6b4413def249c0b0ded2a07541cdd89597ada34d6d4d93eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756144779,
      "headline": "FDA Flags Alarming Contamination At Novo Nordisk Indiana Plant, Including Cat Hair, Bacteria, And Foreign Particles",
      "id": 136523332,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The U.S. Food and Drug Administration (FDA) has identified repeated quality control failures, including foreign particle contamination, inadequate investigations, and insufficient corrective actions at the Novo Nordisk A/S (NYSE:NVO) operated facility in Bloomington, Indiana. In 2024, Novo Nordisk acquired three fill-finish sites from Novo Holdings A/S for $11 billion. The acquisition was part of a larger deal where Novo Holdings acquired Catalent, Inc. (NYSE:CTLT). The three sites, located in A",
      "url": "https://finnhub.io/api/news?id=9d25aa61667a4b9a6b4413def249c0b0ded2a07541cdd89597ada34d6d4d93eb"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors",
    "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=dc2410776fc44908a27378d8c0a0592f3add836b285b665f4feef6513890b68d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756140240,
      "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors",
      "id": 136547207,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=dc2410776fc44908a27378d8c0a0592f3add836b285b665f4feef6513890b68d"
    }
  },
  {
    "ts": null,
    "headline": "Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib",
    "summary": "- Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung cancer – CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a clinical supply agreement with Eli Lilly and Company (NYSE:LLY) for its second-generation KRAS G12C inhibitor, olomorasib (LY3537982). The supply agreement supports",
    "url": "https://finnhub.io/api/news?id=f10d74942a2499fcbfcdebd4a95b8253bb4a013b302c11f07a3b6ea7320959f6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756123200,
      "headline": "Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib",
      "id": 136507904,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "- Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung cancer – CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a clinical supply agreement with Eli Lilly and Company (NYSE:LLY) for its second-generation KRAS G12C inhibitor, olomorasib (LY3537982). The supply agreement supports",
      "url": "https://finnhub.io/api/news?id=f10d74942a2499fcbfcdebd4a95b8253bb4a013b302c11f07a3b6ea7320959f6"
    }
  }
]